Pap Smear — How It Works, Benefits & Recovery — Procedure Guide, Recovery & Risks | MyMedicPlus

A Pap smear (Papanicolaou test) is a cervical cancer screening procedure in which cells from the cervix are collected and examined under a microscope for abnormal changes. It detects precancerous lesions (CIN — cervical intraepithelial neoplasia) before they develop into invasive cancer, enabling curative treatment of early-stage disease. Named after Greek-American physician Georgios Papanikolaou who developed the test in the 1940s, it remains the most impactful cancer screening test ever deployed: countries with organised, population-based Pap smear screening programmes have reduced cervical cancer incidence and mortality by 60–80% over the past 50 years. Modern laboratories use liquid-based cytology (LBC), in which the clinician collects cells into a liquid transport medium rather than smearing them on a glass slide — LBC reduces preparation artefacts, allows the same sample to be used for both cytology and HPV testing, and produces fewer inadequate samples than conventional smears. Human papillomavirus (HPV) causes over 99% of cervical cancers. In most high-income countries, primary HPV testing (testing the cervical sample for high-risk HPV strains before performing cytology) has now replaced or supplemented the traditional Pap smear, as it provides higher sensitivity and allows longer screening intervals. Countries including the UK, Australia, and the Netherlands have transitioned to 5-yearly HPV primary screening in women over 25–30.

Pap smears (or primary HPV tests) are recommended for all individuals with a cervix between defined age limits. Recommendations vary by country: in the United States, the USPSTF (2023) recommends Pap smear alone every 3 years for women aged 21–29, or combined Pap plus HPV co-testing every 5 years (or HPV test alone every 5 years) for women aged 30–65. In England, the NHS Cervical Screening Programme invites women and individuals with a cervix aged 25–64: 3-yearly from 25–49, then 5-yearly from 50–64 (now using HPV primary testing with cytology triage for HPV-positive samples). Screening is recommended regardless of HPV vaccination status, as vaccines do not protect against all carcinogenic HPV strains. More frequent screening (annually) is indicated after: recent abnormal Pap results requiring surveillance, history of CIN2 or higher treatment, immunocompromise (HIV infection, immunosuppressive therapy), and in utero diethylstilboestrol (DES) exposure. Women who have had a total hysterectomy for non-cancerous conditions and have no prior history of CIN2 or cervical cancer may discontinue screening. Screening is discontinued at 65 (US) or 64 (UK) in women with adequate prior normal screening history.

The procedure takes approximately 5 minutes and is performed in the clinic or GP surgery. The patient is asked to undress from the waist down and lie on the examination table with knees bent and feet in stirrups or flat on the table. A speculum (a smooth plastic or metal device) is gently inserted into the vagina and opened to visualise the cervix — the smooth, doughnut-shaped lower end of the uterus. The clinician uses a small soft brush (cervical broom or Cervex-Brush) and/or an endocervical brush to sweep cells from the transformation zone — the junction between the columnar endocervical epithelium and the squamous ectocervical epithelium where precancerous changes develop — and the endocervical canal. The tip of the brush is rinsed into a small vial of liquid transport medium (e.g., ThinPrep or SurePath), which is sealed and sent to the cytology laboratory. The speculum is gently removed. For primary HPV testing, the same sample is first tested for high-risk HPV DNA by PCR; if HPV-positive, the same liquid sample is then processed for cytology. A small amount of light vaginal spotting after the procedure is normal and expected. Results are typically reported within 1–2 weeks. The Bethesda System 2014 is used for reporting cervical cytology results. Normal results include negative for intraepithelial lesion (NIL) and unsatisfactory (requiring repeat). Abnormal results include ASC-US (atypical squamous cells of undetermined significance), LSIL (low-grade squamous intraepithelial lesion), HSIL (high-grade squamous intraepithelial lesion), ASC-H, and AGC (atypical glandular cells). Results are available within 1–2 weeks.

The Pap smear is one of the most effective cancer screening tests in medical history. Population-based cervical screening programmes have reduced cervical cancer incidence by 60–80% and mortality by over 70% in countries with organised screening — preventing approximately 5,000 cervical cancer deaths per year in the UK alone that would otherwise occur. The test detects CIN (precancerous changes) at a stage when they are completely curable by a simple outpatient procedure (LLETZ — large loop excision of the transformation zone), avoiding the need for more aggressive cancer treatment. A Pap smear with HPV co-testing achieves a combined sensitivity of over 95% for detecting high-grade cervical precancerous lesions (CIN2+) and a negative predictive value approaching 100%, allowing safe extension of the screening interval to 5 years in HPV-negative women. The procedure itself is inexpensive, takes 5 minutes, requires no anaesthesia, involves no recovery, and is available in primary care. The introduction of HPV vaccination (protecting against HPV 16 and 18, causing 70% of cervical cancers) alongside ongoing screening provides complementary protection — Australia, where HPV vaccination and organised screening have both been systematically implemented, is projected to achieve cervical cancer elimination (fewer than 4 cases per 100,000 women per year) before 2028.

A Pap smear carries essentially no physical risk. Mild transient cramping similar to period pain during the speculum examination resolves within minutes. Light spotting for up to 24 hours after the procedure is normal. The principal clinical limitations are false-negative and false-positive results. The false-negative rate for cytology alone is approximately 15–20%, meaning some precancerous lesions may not be detected on a single test — this limitation underpins the recommendation for regular repeated screening rather than a single lifetime test. The false-positive rate is approximately 5–10% for low-grade abnormalities (ASCUS, LSIL) which cause anxiety and lead to referral for colposcopy, most of which confirm no significant pathology or changes that resolve spontaneously without treatment. Over-treatment of low-grade lesions is a recognised concern, particularly given evidence that treatment with LLETZ (cervical excision) increases the risk of preterm birth in future pregnancies by approximately 1.7-fold. Modern risk-stratified management guidelines (British Society for Colposcopy and Cervical Pathology, ASCCP) use combined HPV genotype and cytology results to triage only higher-risk women for colposcopy, reducing the burden of unnecessary colposcopies.

There is no recovery period after a Pap smear. Patients return to all normal activities immediately, including work, driving, and sexual activity. A small amount of light spotting or bloody discharge for up to 24–48 hours after the test is normal — it results from gentle trauma to the cervical transformation zone by the brush and does not indicate any problem. Routine hygiene products (tampons, menstrual cups) can be used from the following day. Results are communicated by post, online patient portal, or telephone within 1–2 weeks. A normal result requires no action until the next scheduled screening. An inadequate result (insufficient or poorly preserved cells — occurring in less than 2% with liquid-based cytology) requires a repeat test in 3 months. An abnormal result will prompt the screening programme to contact the patient explaining the specific finding and the recommended management, ranging from early repeat testing (low-grade changes) to urgent colposcopy referral (high-grade changes). Women should be aware that an abnormal result does not mean cancer — the vast majority represent pre-cancerous changes or minor inflammation that resolves or is easily treated.